Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ARDX
Ardelyx, Inc. (ARDX) EV/Sales
As of 16 October 2026, Ardelyx, Inc. (ARDX) trades at a EV/Sales of 1.7×. Over the past ten years it has ranged from −13.6× (December 2018) to 1,054× (September 2019); the current reading is higher than 4% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.4× | 0.18% |
| FY2024 | 3.4× | (65.73%) |
| FY2023 | 9.8× | 48.06% |
| FY2022 | 6.6× | 67.27% |
| FY2021 | 4.0× | (93.25%) |
| FY2020 | 58.6× | 9.72% |
| FY2019 | 53.4× | — |
| FY2018 | −7.0× | — |
| FY2017 | 6.5× | (35.65%) |
| FY2015 | 10.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.8× | (18.29%) |
| Mar 2026 | 3.4× | 1.82% |
| Dec 2025 | 3.4× | 1.55% |
| Sep 2025 | 3.3× | 37.48% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| ARDX Ardelyx, Inc. | 1.7× |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 3.0× |
| GERN Geron Corporation compare | 3.3× |
| KURA Kura Oncology, Inc. compare | 3.9× |
| VSTM Verastem, Inc. compare | 9.3× |
| ALMS Alumis Inc. compare | 37.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)